Digitisation | January 10, 2026
Revvity and Lilly partner to accelerate AI drug discovery models
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The approval introduces a needle-free alternative to injectable GLP-1 therapies
India’s pharmaceutical sector stands at a pivotal inflection point
The state-of-the-art laboratory opens at the Corewell Health Southfield Center in early 2027
Subscribe To Our Newsletter & Stay Updated
